• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Nuwellis Inc. (Amendment)

    2/3/22 4:46:53 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NUWE alert in real time by email
    SC 13G/A 1 sc13ga110022002_02032022.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    Nuwellis, Inc. f/k/a CHF Solutions, Inc.

     (Name of Issuer)

    Common Stock, par value $0.0001 per share

     (Title of Class of Securities)

    67113Y108

     (CUSIP Number)

    December 31, 2021

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 67113Y108

     

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         65,994 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              65,994 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            65,994 shares of Common Stock issuable upon exercise of Warrants (See Item 4)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent*  
      12   TYPE OF REPORTING PERSON  
             
            PN  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker. The percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s outstanding Common Stock held by the Reporting Person after reflecting for the exercise of the Warrants. In addition, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers.

      

    2

    CUSIP No. 67113Y108

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         65,994 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              65,994 shares of Common Stock issuable upon exercise of Warrants (See Item 4)  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            65,994 shares of Common Stock issuable upon exercise of Warrants (See Item 4)  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent*  
      12   TYPE OF REPORTING PERSON  
             
            OO  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s outstanding Common Stock held by the Reporting Person after reflecting for the exercise of the Warrants. In addition, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers.

      

    3

    CUSIP No. 67113Y108

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.6%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s outstanding Common Stock held by the Reporting Person after reflecting for the exercise of the Warrants. In addition, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers.

      

    4

    CUSIP No. 67113Y108

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.6%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s outstanding Common Stock held by the Reporting Person after reflecting for the exercise of the Warrants. In addition, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers.

      

    5

    CUSIP No. 67113Y108

     

      1   NAME OF REPORTING PERSON  
             
            District 2 GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.6%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s outstanding Common Stock held by the Reporting Person after reflecting for the exercise of the Warrants. In addition, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers.

      

    6

    CUSIP No. 67113Y108

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            161,549 shares of Common Stock
    3,333 shares issuable upon exercise of Warrants (See Item 4)
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.6%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

    * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) constitutes the percentage ownership of the Issuer’s outstanding Common Stock held by the Reporting Person after reflecting for the exercise of the Warrants. In addition, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers.

      

    7

    CUSIP No. 67113Y108

     

      1   NAME OF REPORTING PERSON  
             
            Michael Bigger  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         100,000 shares of Common Stock  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         161,549 shares of Common Stock*
    69,327 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              100,000 shares of Common Stock  
        8   SHARED DISPOSITIVE POWER  
               
              161,549 shares of Common Stock*
    69,327 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            261,549 shares of Common Stock*
    69,327 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            2.2%*  
      12   TYPE OF REPORTING PERSON  
             
            IN  

    * Consists of 65,994 shares of Common Stock issuable upon exercise of Warrants owned by Bigger Capital, 161,549 shares of Common Stock owned by District 2 CF, 3,333 shares of Common Stock issuable upon exercise of Warrants owned by District 2 CF and 100,000 shares held through an IRA of Mr. Bigger. As more fully described in Item 4, the Warrants are subject to a 4.99% blocker, and the percentage set forth in row (11) does not give effect to such blockers. In addition, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon the exercise of all such Warrants and do not give effect to such blockers.

      

    8

    CUSIP No. 67113Y108

    Item 1(a).Name of Issuer:

    Nuwellis, Inc., a Delaware corporation (the “Issuer”).

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    12988 Valley View Road
    Eden, Prairie, MN 55344

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

    Bigger Capital Fund, LP (“Bigger Capital”)
    2250 Red Springs Drive
    Las Vegas, NV 89135
    Citizenship: Delaware

    Bigger Capital Fund GP, LLC (“Bigger GP”)
    2250 Red Springs Drive
    Las Vegas, NV 89135
    Citizenship: Delaware

    Michael Bigger
    2250 Red Springs Drive
    Las Vegas, NV 89135
    Citizenship: USA

    District 2 Capital Fund LP (“District 2 CF”)
    175 W Carver Street
    Huntington, NY 11743
    Citizenship: Delaware

    District 2 Capital LP (“District 2”)
    175 W Carver Street
    Huntington, NY 11743
    Citizenship: Delaware

    District 2 GP LLC (“District 2 GP”)
    175 W Carver Street
    Huntington, NY 11743
    Citizenship: Delaware

    District 2 Holdings LLC (“District 2 Holdings”)
    175 W Carver Street
    Huntington, NY 11743
    Citizenship: Delaware

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    9

    CUSIP No. 67113Y108

    Item 2(d).Title of Class of Securities:

    Common Stock, $0.0001 par value (the “Common Stock”).

    Item 2(e).CUSIP Number:

    67113Y108

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
           
          If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership
    (a)Amount beneficially owned:

    As of December 31, 2021, Bigger Capital beneficially owned 65,994 shares of Common Stock issuable upon the exercise of Warrants at varying exercise prices (the “Warrants”).

    10

    CUSIP No. 67113Y108

    Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own 65,994 shares of Common Stock issuable upon exercise of Warrants beneficially owned by Bigger Capital.

    As of December 31, 2021, District 2 CF beneficially owned 161,549 shares of Common Stock and 3,333 shares issuable upon the exercise of Warrants.

    District 2, as the investment manager of District 2 CF, may be deemed to beneficially own the 161,549 shares of Common Stock and 3,333 shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    District 2 GP, as the general partner of District 2 CF, may be deemed to beneficially own the 161,549 shares of Common Stock and 3,333 shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    District 2 Holdings, as the managing member of District 2 GP, may be deemed to beneficially own the 161,549 shares of Common Stock and 3,333 shares issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    Mr. Bigger, as the managing member of Bigger GP and the managing member of District 2 Holdings, may be deemed to beneficially own (i) 65,994 shares of Common Stock issuable upon exercise of Warrants owned by Bigger Capital, (ii) 161,549 shares of Common Stock, and (iii) 3,333 shares of Common Stock issuable upon exercise of Warrants owned by District 2 CF. In addition, Mr. Bigger through an IRA owns 100,000 shares of Common Stock.

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by Bigger Capital. Each of District 2, District 2 GP, District 2 Holdings and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by District 2 CF, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

    (b)Percent of class:

    The following percentages are based on 10,537,606 shares of Common Stock outstanding as of November 5, 2021, as reputed in the Company’s Form 10-Q for the period ended September 30, 2021 filed on November 10, 2021 with the Securities Exchange Commission. In addition, the foregoing reflects with respect to (i) Bigger Capital and Bigger GP, the exercise of Warrants to Purchase 65,994 shares (ii) District 2 CF, District 2, District 2 GP and District 2 Holdings, the exercise of Warrants to purchase 3,333 shares and (iii) with respect to Mr. Bigger, the exercise of the Warrants reflected in (i) and (ii).

    As of the close of business on December 31, 2021, (i) each of Bigger Capital and Bigger GP may be deemed to beneficially own less than one percent of the outstanding shares of Common Stock, (ii) each of District 2 CF, District 2, District 2 GP, and District 2 Holdings may be deemed to collectively beneficially own 1.6% of the outstanding shares of Common Stock, and (iii) Mr. Bigger may be deemed to own approximately 2.2% of the outstanding shares of Common Stock.

    11

    CUSIP No. 67113Y108

    Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons or affiliates of the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock.

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (ii)Shared power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (iii)Sole power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    (iv)Shared power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    Item 5.Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:[x].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8.Identification and Classification of Members of the Group.

    See Exhibit 99.1. Previously Filed.

    Item 9.Notice of Dissolution of Group.

    Not Applicable.

    Item 10.Certifications.

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    12

    CUSIP No. 67113Y108

    SIGNATURE

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 3, 2022

    BIGGER CAPITAL FUND, LP   BIGGER CAPITAL FUND GP, LLC
         
    By: Bigger Capital Fund GP, LLC, its general partner   By:

    /s/ Michael Bigger

            Michael Bigger
    By:

    /s/ Michael Bigger

        Managing Member
      Michael Bigger      
      Managing Member      
          DISTRICT 2 CAPITAL LP
             
    DISTRICT 2 CAPITAL FUND LP   By:

    /s/ Michael Bigger

            Michael Bigger
    By: District 2 GP LLC, its general partner     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger   DISTRICT 2 HOLDINGS LLC
      Managing Member      
          By:

    /s/ Michael Bigger

            Michael Bigger
    DISTRICT 2 GP LLC     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger  

    /s/ Michael Bigger

      Managing Member   Michael Bigger

    13

     

    Get the next $NUWE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUWE

    DatePrice TargetRatingAnalyst
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em

      5/13/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Contracts with KDI Precision Manufacturing to Strengthen Production and Improve Operational Efficiency

      Strategic agreement is expected to reduce costs, preserve expertise, and streamline operations. WHOWHATWHEREWHENWHYNuwellis, Inc. (NASDAQ:NUWE) and KDI Precision ManufacturingOutsourcing manufacturing and assembly of key Aquadex product components.Manufacturing operations will transition to KDI's facility.May 9, 2025To strengthen operational efficiency, preserve product expertise, and reduce costs. MINNEAPOLIS, May 12, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming fluid management care, today announced it has finalized an agreement with KDI Precision Manufacturing to support the next phase of Nuwellis' growth. This strateg

      5/12/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced a meaningful step forward for children facing fluid overload with the recent expansion of its Aquadex SmartFlow® therapy into two additional pediatric centers across the Southeastern United States. The company now has 47 pediatric centers that have adopted Aquadex therapy as part of their fluid management approach. Even in well-managed care settings, fluid overload can be a turning point in recovery for pediatric patients—who often have a narrow margin for error. When alternative therapies fall

      5/8/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nuwellis Inc.

      10-Q - Nuwellis, Inc. (0001506492) (Filer)

      5/13/25 5:00:43 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      5/13/25 11:00:41 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      5/12/25 4:45:22 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

      MINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of Interim President and Chief Executive Officer and assumed all of the duties formerly performed by Mr. Jaramillo. Nuwellis intends to retain an executive search firm to assist in identifying a permanent CEO. Mr. Erb, stated, "Nestor has been with the company for nearly si

      2/24/25 4:05:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces Board of Directors Transition

      MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. "With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board. Dave's significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives. In turn, our board will benefit from perspectives gained from Archelle's healthcare policy, clinical, and patient education experience

      11/1/23 8:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

      MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company's Board of Directors. Mr. McCormick's vast experience includes more than 25 years of service in the medical device industry through varying leadership roles for several private and publicly traded companies. Mr. McCormick will also serve as Lead Independent Director and serve as a member of the Audit Committee and as Chair of the Nominating and Corporate Governance Committee of the Board. "We are delighted to welcome Mike to Nuwellis' Board

      6/5/23 4:15:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Financials

    Live finance-specific insights

    See more
    • Nuwellis, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em

      5/13/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

      MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-579-2543 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ1. An a

      4/22/25 4:04:59 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

      MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics.Full year operating cost reduction of $5.9 million, or 26%, compared to the pr

      3/11/25 8:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mccormick Michael Kendrick

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:25:39 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Mcdonald David

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:21:51 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Feldshon Archelle Georgiou

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:16:08 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      8/30/24 4:11:06 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      8/2/24 4:12:11 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      5/6/24 4:01:02 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Nuwellis with a new price target

      ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

      7/29/24 7:42:07 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care